Global Alliance for TB Drug Development
room 40 Wall Street, Floor 24, New York 10005
arrow_back See all Activities

Advance novel TB drug regimens

IATI Identifier: US-EIN-13-4128413-Gpaf-2016

Published on IATI
  • date_range Apr 01, 2013
  • autorenew Implementation (Status)

TB Alliance is focused on: 1. Improved TB therapeutic regimens that are developed, registered, and available to those who need them -- making a major impact on the global TB pandemic 2. Progress is made on the development of new compounds that offer promise to hit novel targets and achieve in vivo cure of TB in optimized combinations in 8-12 weeks and the best potential combinations are assessed for clinical regimen development.

more_horiz
Sectors:

Participating Organisations

Department of International Development, United Kingdom (UKAID) Government Funding

Transaction

Transaction Value Provider
Receiver
Type Date
54,033,661 USD Provider N/A Receiver N/A Expenditure
date_range Dec 31, 2016

Budget

114,799,834 USD
  • 50,116,067 USD (Valued at Aug 21, 2017)
    date_range Jan 01, 2017 - Dec 31, 2017
  • 10,880,010 USD (Valued at Aug 21, 2017)
    date_range Jan 01, 2018 - Dec 31, 2018
  • 53,803,757 USD (Valued at Aug 22, 2017)
    date_range Jan 01, 2016 - Dec 31, 2016
access_time Updated on Aug 23, 2017 16:38:10
View XML file here